X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs WOCKHARDT - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA WOCKHARDT AUROBINDO PHARMA/
WOCKHARDT
 
P/E (TTM) x 15.4 -18.4 - View Chart
P/BV x 3.1 1.3 241.4% View Chart
Dividend Yield % 0.4 0.0 13,447.6%  

Financials

 AUROBINDO PHARMA   WOCKHARDT
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
WOCKHARDT
Mar-18
AUROBINDO PHARMA/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs8091,012 79.9%   
Low Rs504532 94.8%   
Sales per share (Unadj.) Rs281.1355.9 79.0%  
Earnings per share (Unadj.) Rs41.4-60.3 -68.6%  
Cash flow per share (Unadj.) Rs50.9-46.8 -108.8%  
Dividends per share (Unadj.) Rs2.500.01 25,000.0%  
Dividend yield (eoy) %0.40 29,388.8%  
Book value per share (Unadj.) Rs199.4257.8 77.3%  
Shares outstanding (eoy) m585.88110.63 529.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.32.2 107.7%   
Avg P/E ratio x15.9-12.8 -124.0%  
P/CF ratio (eoy) x12.9-16.5 -78.2%  
Price / Book Value ratio x3.33.0 110.0%  
Dividend payout %6.00 -36,439.0%   
Avg Mkt Cap Rs m384,63085,379 450.5%   
No. of employees `00017.36.3 277.1%   
Total wages/salary Rs m21,3089,371 227.4%   
Avg. sales/employee Rs Th9,500.76,295.0 150.9%   
Avg. wages/employee Rs Th1,229.41,498.3 82.1%   
Avg. net profit/employee Rs Th1,397.9-1,066.3 -131.1%   
INCOME DATA
Net Sales Rs m164,66639,369 418.3%  
Other income Rs m1,0201,202 84.8%   
Total revenues Rs m165,68640,571 408.4%   
Gross profit Rs m37,71818 206,106.6%  
Depreciation Rs m5,5801,495 373.1%   
Interest Rs m7772,555 30.4%   
Profit before tax Rs m32,380-2,830 -1,144.3%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m8,183257 3,183.9%   
Profit after tax Rs m24,229-6,669 -363.3%  
Gross profit margin %22.90 49,276.8%  
Effective tax rate %25.3-9.1 -278.2%   
Net profit margin %14.7-16.9 -86.9%  
BALANCE SHEET DATA
Current assets Rs m121,87833,796 360.6%   
Current liabilities Rs m86,80626,917 322.5%   
Net working cap to sales %21.317.5 121.9%  
Current ratio x1.41.3 111.8%  
Inventory Days Days13079 163.7%  
Debtors Days Days6889 76.6%  
Net fixed assets Rs m81,03739,664 204.3%   
Share capital Rs m586553 105.9%   
"Free" reserves Rs m116,21827,968 415.5%   
Net worth Rs m116,80428,522 409.5%   
Long term debt Rs m4,51221,731 20.8%   
Total assets Rs m211,05281,620 258.6%  
Interest coverage x42.7-0.1 -39,679.4%   
Debt to equity ratio x00.8 5.1%  
Sales to assets ratio x0.80.5 161.8%   
Return on assets %11.8-5.0 -235.1%  
Return on equity %20.7-23.4 -88.7%  
Return on capital %27.4-7.7 -356.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,7279,807 823.2%   
Fx outflow Rs m34,7001,789 1,940.1%   
Net fx Rs m46,0278,019 574.0%   
CASH FLOW
From Operations Rs m19,548684 2,856.3%  
From Investments Rs m-19,5706,302 -310.5%  
From Financial Activity Rs m8,642-7,695 -112.3%  
Net Cashflow Rs m8,922-664 -1,343.7%  

Share Holding

Indian Promoters % 54.1 74.5 72.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 2.3 345.7%  
FIIs % 27.7 7.7 359.7%  
ADR/GDR % 0.0 0.1 -  
Free float % 10.2 15.4 66.2%  
Shareholders   69,601 67,757 102.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   SANOFI INDIA  TORRENT PHARMA  PLETHICO PHARMA  CIPLA  ABBOTT INDIA  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Lower; IT Stocks Under Pressure(09:30 am)

Asian share markets edged near this year's peak while benchmark US treasury yields, and the dollar dropped after the Federal Reserve signaled possible interest rate cuts later this year.

Related Views on News

WOCKHARDT Plunges by 7%; BSE HEALTHCARE Index Down 0.4% (Market Updates)

Jun 20, 2019 | Updated on Jun 20, 2019

WOCKHARDT share price has plunged by 7% and its current market price is Rs 340. The BSE HEALTHCARE is down by 0.4%. The top gainers in the BSE HEALTHCARE Index are ERIS LIFESCIENCES LIMITED (up 2.6%) and APOLLO HOSPITALS (up 2.1%). The top losers is WOCKHARDT (down 6.9%)..

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)

Jan 29, 2019 | Updated on Jan 29, 2019

For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jun 20, 2019 11:17 AM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS